image
Healthcare - Drug Manufacturers - General - NASDAQ - GB
$ 63.23
-2.78 %
$ 196 B
Market Cap
30.69
P/E
1. INTRINSIC VALUE

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19.[ Read More ]

The intrinsic value of one AZN stock under the base case scenario is HIDDEN Compared to the current market price of 63.2 USD, AstraZeneca PLC is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart AZN

image
FINANCIALS
45.8 B REVENUE
3.29%
8.19 B OPERATING INCOME
118.07%
6.9 B NET INCOME
175.85%
10.3 B OPERATING CASH FLOW
5.48%
-4.06 B INVESTING CASH FLOW
-37.30%
-6.57 B FINANCING CASH FLOW
3.75%
12.9 B REVENUE
2.04%
2.84 B OPERATING INCOME
-12.48%
1.93 B NET INCOME
-11.56%
3.2 B OPERATING CASH FLOW
24.00%
-2.87 B INVESTING CASH FLOW
-14.60%
-1.22 B FINANCING CASH FLOW
-60.26%
Balance Sheet Decomposition AstraZeneca PLC
image
Current Assets 25.1 B
Cash & Short-Term Investments 5.86 B
Receivables 8.41 B
Other Current Assets 10.8 B
Non-Current Assets 76.1 B
Long-Term Investments 1.78 B
PP&E 10.5 B
Other Non-Current Assets 63.8 B
Current Liabilities 30.5 B
Accounts Payable 3.27 B
Short-Term Debt 6.39 B
Other Current Liabilities 20.9 B
Non-Current Liabilities 31.4 B
Long-Term Debt 23.2 B
Other Non-Current Liabilities 8.19 B
EFFICIENCY
Earnings Waterfall AstraZeneca PLC
image
Revenue 45.8 B
Cost Of Revenue 8.27 B
Gross Profit 37.5 B
Operating Expenses 29.6 B
Operating Income 8.19 B
Other Expenses 1.29 B
Net Income 6.9 B
RATIOS
81.95% GROSS MARGIN
81.95%
17.88% OPERATING MARGIN
17.88%
13.00% NET MARGIN
13.00%
15.21% ROE
15.21%
5.89% ROA
5.89%
10.47% ROIC
10.47%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis AstraZeneca PLC
image
Net Income 6.9 B
Depreciation & Amortization 4.93 B
Capital Expenditures -3.78 B
Stock-Based Compensation 579 M
Change in Working Capital 300 M
Others -2.37 B
Free Cash Flow 6.57 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets AstraZeneca PLC
image
Wall Street analysts predict an average 1-year price target for AZN of $86 , with forecasts ranging from a low of $82 to a high of $89 .
AZN Lowest Price Target Wall Street Target
82 USD 29.69%
AZN Average Price Target Wall Street Target
86 USD 36.01%
AZN Highest Price Target Wall Street Target
89 USD 40.76%
4. DIVIDEND ANALYSIS
0.01% DIVIDEND YIELD
0.49 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership AstraZeneca PLC
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC - AZN NEW YORK, NY / ACCESSWIRE / November 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ:AZN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accesswire.com - 19 hours ago
Vaccine Maker Stocks Slump After RFK Jr. Nominated as HHS Head In the 2024 presidential election's latest impact on the stock markets, shares of several vaccine makers were down Friday morning following the nomination of Robert F. Kennedy Jr. to head the Department of Health and Human Services. investopedia.com - 1 day ago
European And US Vaccine Stocks Are Under Pressure - Here's WHy Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services. benzinga.com - 1 day ago
AstraZeneca PLC Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - AZN NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company. accesswire.com - 2 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC - AZN NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ:AZN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accesswire.com - 2 days ago
Bullish Opportunities in AZN Tony Zhang with @OptionsPlay says AstraZeneca (AZN) has more going for it than its stock chart may show. Following the company's latest earnings, he points to strength in key metrics as a sign for bulls to charge. youtube.com - 2 days ago
Lost Money on AstraZeneca PLC (AZN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company. accesswire.com - 3 days ago
Is AstraZeneca a Buy as It Eyes the Weight Loss Market? AstraZeneca just released some encouraging data about its weight loss drug candidates. fool.com - 3 days ago
AstraZeneca: Strong Growth Potential And Market Volatility Offer Opportunity AstraZeneca PLC aims for $80 billion revenue by 2030, driven by strong growth in oncology, biopharmaceuticals, and rare diseases, despite recent share price declines. The company's weight management pipeline, including AZD5004 and AZD6234, shows significant growth potential, especially with strategic hires and advancements in clinical trials. Financial performance in Q3 2024 was robust, with a 21% revenue increase, supporting the company's ambitious long-term goals despite increased operating expenses. seekingalpha.com - 3 days ago
Healthy Returns: AstraZeneca expands U.S. investment plan on confidence in economy AstraZeneca said it is doubling down on its investment in its U.S. business. Meanwhile, General Catalyst has agreed to purchase Summa Health for $485 million. cnbc.com - 3 days ago
AstraZeneca Beats on Q3 Earnings, Ups 2024 View, to Invest $3.5B in US AZN beats third-quarter estimates for earnings and sales. It raises its sales and profit outlook for 2024 for the second time this year. zacks.com - 4 days ago
Levi & Korsinsky Announces an Investigation on Behalf of AstraZeneca PLC (AZN) Shareholders Who May Have Been Affected by Fraud NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company. accesswire.com - 4 days ago
8. Profile Summary

AstraZeneca PLC AZN

image
COUNTRY GB
INDUSTRY Drug Manufacturers - General
MARKET CAP $ 196 B
Dividend Yield 0.01%
Description AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Contact 1 Francis Crick Avenue, Cambridge, CB2 0AA https://www.astrazeneca.com
IPO Date May 12, 1993
Employees 89900
Officers Dr. Ruud Dobber Ph.D. Executive Vice-President of BioPharmaceuticals Business Unit Dr. Aradhana Sarin M.D. Chief Financial Officer & Executive Director Mr. David Fredrickson Executive Vice-President of Oncology Business Unit Mr. Andrew P. Barnett Head of Investor Relations Ms. Iskra Reic Executive Vice-President of Vaccines & Immune Therapies Dr. Susan Mary Galbraith M.D., Ph.D. Executive Vice President of Oncology Research & Development Mr. Leon Wang Executive Vice President of International & China President Ms. Pam P. Cheng EVice President of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board Gonzalo Vina Head of Global Media Relations Mr. Pascal Soriot D.V.M., M.B.A. Chief Executive Officer & Executive Director